Trial Profile
a phase I study to assess safety, tolerability and immunogenicity of a trivalent influenza vaccine administered by particle mediated epidermal delivery (PMED) to healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs Influenza virus DNA vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Pfizer
- 04 Oct 2006 New trial record.